Chinese pharma must use collaborative deals to leverage IP expertise

The recent spate of partnerships agreed between Western and Chinese pharmaceutical businesses underscores the continued need for collaboration to fully leverage the Chinese market. But while foreign life sciences companies pursue joint ventures with…

Get unlimited access to all IAM content